Drugs News and Research

RSS

Conference examines lagging ethical guidelines in face of expanding clinical trials in developing countries

SciDev.Net reports on the 7th World Conference of Science Journalists, taking place this week in Qatar, where participants discussed how the number of clinical trials in developing countries is surging despite legal and ethical frameworks often not being in place.

30 Jun 2011

Dems reject plan to cut Medicare costs, raise eligibility age

As negotiations over raising the nation's debt ceiling continue, two senators — Tom Coburn, R-Okla., and Joseph Lieberman, I-Conn. — advanced a new plan to produce the amount of savings from the Medicare program needed to meet the debt reduction target. The approach, though, which includes raising the eligibility age to 67, was swiftly rejected by top Democrats.

30 Jun 2011

TCGA examines ovarian serous adenocarcinoma tumors from 500 patients

An analysis of genomic changes in ovarian cancer has provided the most comprehensive and integrated view of cancer genes for any cancer type to date. Ovarian serous adenocarcinoma tumors from 500 patients were examined by The Cancer Genome Atlas (TCGA) Research Network and analyses are reported in the June 30, 2011, issue of Nature.

30 Jun 2011

HHS: Half million seniors experiencing lower drug costs

As a result of health law changes to provide seniors with "doughnut hole" relief, Medicare recipients saved a combined $260 million on medicines as of the end of last month.

30 Jun 2011

FDA's ODAC recommends withdrawal of Avastin approval for metastatic breast cancer

Genentech, a member of the Roche Group, announced today that, during a U.S. Food and Drug Administration (FDA) hearing, the FDA's Oncologic Drugs Advisory Committee (ODAC) recommended that the FDA withdraw its approval of Avastin in combination with paclitaxel chemotherapy for previously untreated HER2-negative metastatic breast cancer.

30 Jun 2011

Dendreon receives FDA approval for Los Angeles cancer immunotherapy manufacturing facility

Dendreon Corporation today announced that the U.S. Food and Drug Administration approved its Los Angeles cancer immunotherapy manufacturing facility, allowing the company to continue to increase the availability of PROVENGE across the U.S. to help meet the needs of patients with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer.

30 Jun 2011

Viewpoints: Calif.'s budget, Supreme Court drug rulings, the Avastin debate

The budget is not realistic, counting on fantastical revenue projections as well as a redevelopment gambit that's likely to be blocked in court. It makes deep cuts in state programs that will have unwelcome repercussions in years to come. And if the revenue projections prove to be as overly optimistic as they seem, there will be more damaging cuts to education, child care and health services. Nevertheless, it's a more earnest effort to clean up the state's budget mess than Sacramento has seen in a decade or more.

30 Jun 2011

Supreme Court rules in favor of ‘pharma’ data mining

The U.S. Supreme Court ruled that the pharmaceutical companies could use the information that they gained from doctors’ prescribing records. The data mining had been restricted in Maine following the high court ruling that struck down a similar law in Vermont.

29 Jun 2011

Patients, scientists in different corners for cancer drug fight

The drug, Avastin, will be the subject of an unusual Food and Drug Administration hearing to revisit a panel vote last July that steered many doctors away from prescribing the drug for the treatment of breast cancer.

29 Jun 2011

Acetylon to advance ACY-1215 drug candidate with $27M Series B Preferred equity investment round of financing

Acetylon Pharmaceuticals, Inc. announced today that it has completed a $27 million Series B Preferred equity investment round of financing.

29 Jun 2011

GenSpera and University of Copenhagen collaborate on 'Sustainable Production of Thapsigargin using Light'

GenSpera, Inc. has entered into a cooperation agreement with the University of Copenhagen, in Copenhagen, Denmark, to collaborate on the "SPOTLight" (Sustainable Production of Thapsigargin using Light) project.

29 Jun 2011

New prostate cancer drugs bring cost of care into spotlight

Meanwhile, results from a three-decade Swedish study found that women who have mammograms have a lower death rate from breast cancer — a finding that some say may ease recent controversies around the screening procedure.

29 Jun 2011

Anacor, DNDi and SCYNEXIS complete SCYX-7158 pre-clinical studies for combating sleeping sickness

Anacor Pharmaceuticals, the Drugs for Neglected Diseases initiative (DNDi), and SCYNEXIS Inc. today announced the successful completion of pre-clinical studies for the first new oral drug candidate discovered specifically to combat human African trypanosomiasis (HAT), also known as sleeping sickness.

29 Jun 2011

Prototype small molecule drugs could suppress hepatitis C

Targeted multi-drug treatments for hepatitis C patients that could stop the virus in its tracks have come a step closer, thanks to researchers at the University of Leeds, UK.

29 Jun 2011

Combination therapies inhibiting P7 could prevent spread of HCV

British researchers have identified specific resistance mutations for two classes of p7 inhibitor, which may explain their lack of effectiveness in clinical trials combined with current standard of care.

29 Jun 2011

Conventional Estrogen Receptor measurement methods may result in 10-20% false negative rate

A team of Yale Cancer Center researchers has confirmed that between 10-20% of breast cancers classified as Estrogen Receptor (ER) negative are really positive. Understanding when and why breast cancers may be misclassified has important implications for treatment and outcomes for women diagnosed with breast cancer. Its findings are published online in the June 28 Journal of Clinical Oncology.

28 Jun 2011

New insights into 'sundowning' syndrome

New research provides the best evidence to date that the late-day anxiety and agitation sometimes seen in older institutionalized adults, especially those with dementia, has a biological basis in the brain.

28 Jun 2011

Bio-Nucleonics' generic Metastron, an option for metastatic cancer bone pain therapy

Bio-Nucleonics' lead product Strontium Chloride Sr-89 Injection USP (Strontium-89), which is the generic version of Metastron®, is an option to consider for metastatic cancer bone pain therapy, typically caused by advanced stage breast, prostate or lung cancer.

28 Jun 2011

Relypsa initiates dosing in RLY5016 Phase 2b trial for hyperkalemia in diabetic nephropathy and CKD patients

Relypsa, Inc. today announced the start of dosing in a Phase 2b clinical trial of RLY5016 for the treatment of hyperkalemia in patients with diabetic nephropathy and chronic kidney disease (CKD). RLY5016 is a high capacity, non-absorbed, polymer-based potassium binder that is orally administered and has been shown to control serum potassium levels in previous studies.

28 Jun 2011

Nine-year-old recovers with experimental heart pump

Nine-year-old Greer Underwood was healthy until February 2011. What seemingly began as sinusitis on a Tuesday became almost fatal by the weekend when her heart began to fail. Now, after a historic series of events at the University of Alabama at Birmingham, she's the only child in the country to have used the experimental heart pump, Heartware, as a bridge to transplant.

28 Jun 2011

Drugs News and Research

Conference examines lagging ethical guidelines in face of expanding clinical trials in developing countries

Dems reject plan to cut Medicare costs, raise eligibility age

TCGA examines ovarian serous adenocarcinoma tumors from 500 patients

HHS: Half million seniors experiencing lower drug costs

FDA's ODAC recommends withdrawal of Avastin approval for metastatic breast cancer

Dendreon receives FDA approval for Los Angeles cancer immunotherapy manufacturing facility

Viewpoints: Calif.'s budget, Supreme Court drug rulings, the Avastin debate

Supreme Court rules in favor of ‘pharma’ data mining

Patients, scientists in different corners for cancer drug fight

Acetylon to advance ACY-1215 drug candidate with $27M Series B Preferred equity investment round of financing

GenSpera and University of Copenhagen collaborate on 'Sustainable Production of Thapsigargin using Light'

New prostate cancer drugs bring cost of care into spotlight

Anacor, DNDi and SCYNEXIS complete SCYX-7158 pre-clinical studies for combating sleeping sickness

Prototype small molecule drugs could suppress hepatitis C

Combination therapies inhibiting P7 could prevent spread of HCV

Conventional Estrogen Receptor measurement methods may result in 10-20% false negative rate

New insights into 'sundowning' syndrome

Bio-Nucleonics' generic Metastron, an option for metastatic cancer bone pain therapy

Relypsa initiates dosing in RLY5016 Phase 2b trial for hyperkalemia in diabetic nephropathy and CKD patients

Nine-year-old recovers with experimental heart pump

Drug Discovery - Second Edition eBook

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News